Study of cevostamab for people with returning or hard-to-treat myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to care for yourself (be up and about most of the day) and have a life expectancy of at least 12 weeks.
- You must have measurable disease, meaning your myeloma can be monitored through blood or urine tests.
- You must be willing to provide bone marrow samples for biopsy and aspiration.
- You need to recover from any side effects of prior cancer treatments before starting.
- If you are of childbearing age, you must agree to use effective birth control or remain abstinent during treatment and for at least 5 months after the last dose, and also follow pregnancy prevention rules if you take pomalidomide.
- If you are male, you must agree to use condoms and not donate sperm during treatment and for at least 2 months after the last dose of tocilizumab (or other required times depending on the study part).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
This trial tests a new combination of two drugs—etentamig given through a vein and a CELMoD pill—for people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if this combination is safe and helps control the disease.
This trial tests a new drug, cevostamab, combined with two standard medicines (pomalidomide and dexamethasone) for people with multiple myeloma who have already had CAR T-cell therapy. It aims to see if this combination can help control the cancer better.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.